title: Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre.
abstract: Direct oral anticoagulants (DOAC) have been shown to be non-inferior to traditional vitamin K antagonists in preventing stroke and arterial thromboembolism in patients with non-valvular atrial fibrillation. Nevertheless, it is mandatory to record side effects and individual adherence to DOAC treatment.
  
  
  
  In this single-centre experience, patients with non-valvular atrial fibrillation were prospectively observed after switching from a vitamin K antagonist to dabigatran or rivaroxaban. The efficacy, safety, and tolerability of the novel treatment, and adherence to it, were evaluated over a period of 1 year. Clinical data were integrated with records of haemorrhagic and non-haemorrhagic complications. All the subjects were given an anonymous self-report questionnaire on the degree of their adherence/satisfaction with the treatment.
  
  
  
  Of 196 patients with non-valvular atrial fibrillation (median age, 78.5 years) who switched from a vitamin K antagonist to DOAC, 178 completed the 1-year follow up, of whom 87 were given dabigatran and 91 rivaroxaban. The efficacy of the two DOAC was similar. Patients given dabigatran had a higher frequency (n=32) of non-haemorrhagic complications (OR: 3.3; 95% CI: 1.7-7.8), which occurred earlier (HR: 6.1; 95% CI: 3.0-12.6) than those (n=7) recorded in subjects on rivaroxaban. The degree of satisfaction with therapy was higher among patients on rivaroxaban (mean score 9.1, SD 1.0) than among those on dabigatran (mean score 8.7; SD 0.9; p=0.01).
  
  
  
  Overall, in this experience, DOAC were shown to be effective, safe alternatives to vitamin K antagonists. Nevertheless, compared with rivaroxaban, dabigatran resulted in a higher rate and earlier occurrence of non-haemorrhagic events, and a lower satisfaction score.
authors.affiliation: Centre for Haemophilia and Rare Bleeding Disorders, "I. Veris delli Ponti" Hospital, Lecce Health Authority, Lecce, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Schiavoni
authors.affiliation: Genetic Medicine, Department of Clinical and Experimental Medicine - Polyclinic Hospital, Foggia, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Margaglione
authors.affiliation: Centre for Haemophilia and Rare Bleeding Disorders, "I. Veris delli Ponti" Hospital, Lecce Health Authority, Lecce, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Coluccia
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011446:Prospective Studies; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects; D011795:Surveys and Questionnaires
chemical_list: D000069552:Rivaroxaban; D000069604:Dabigatran